The neuropathic pain market

Nature Reviews Drug Discovery

Volumn 11, Issue 2, 2012, Pages 101-102

  Nightingale, Sarah ^a  

^a Datamonitor   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKET; AMITRIPTYLINE; ANESTHETIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARC 4558; AVP 923; BUPIVACAINE; CAPSAICIN; CLONIDINE; DULOXETINE; GABAPENTIN; GABAPENTIN ENACARBIL; GENERIC DRUG; KETAMINE; LIDOCAINE; NARCOTIC ANALGESIC AGENT; NUCYNTA ER; PREGABALIN; RALFINAMIDE; TAPENTADOL; UNCLASSIFIED DRUG;

DIABETIC NEUROPATHIC PAIN; DIZZINESS; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; HUMAN; LOW BACK PAIN; NEUROPATHIC PAIN; NOTE; OFF LABEL DRUG USE; POSTHERPETIC NEURALGIA; PRESCRIPTION; PRIORITY JOURNAL; SEDATION; SIDE EFFECT; TREATMENT RESPONSE;

ANALGESICS; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; NEURALGIA;

EID: 84856425935     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3624     Document Type: Note

References (2)

1. Datamonitor. Epidemiology: Peripheral Neuropathic pain-A common co-morbidity for HIV, diabetes, and herpes zoster. HC00221-001 (October 2011)
2. Datamonitor. R&D Trends: Neuropathic pain-Extensive and diverse pipeline driven by high unmet need. HC00064-006 (July 2011).